Abstract：
:Nonsteroidal anti-inflammatory drugs are among the most common drugs associated with drug-induced liver injury, with an estimated incidence of between 3 and 23 per 100,000 patient years. Nimesulide, sulindac, and diclofenac seem to be associated with the highest risk and the only risk factor consistently identified is the concomitant use of other hepatotoxic drugs. Diclofenac-induced liver injury is a paradigm for drug-related hepatotoxicity. Recent studies suggest that genetic factors favoring the formation and accumulation of the reactive acylglucuronide metabolite of diclofenac and an enhanced immune response to the metabolite-protein adducts are associated with increased susceptibility to hepatotoxicity.
journal_name
Clin Liver Disjournal_title
Clinics in liver diseaseauthors
Aithal GP,Day CPdoi
10.1016/j.cld.2007.06.004subject
Has Abstractpub_date
2007-08-01 00:00:00pages
563-75, vi-viiissue
3eissn
1089-3261issn
1557-8224pii
S1089-3261(07)00047-5journal_volume
11pub_type
杂志文章,评审abstract：:Serologic assays for HBV are the mainstay diagnostic tools for HBV infection. However, the advent of molecular biology-based techniques has added a new dimension to the diagnosis and treatment of patients with chronic HBV infection. Over the past decade, improvements in molecular technology, permitting detection of as...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2004.02.001
更新日期：2004-05-01 00:00:00
abstract：:The diagnosis of hepatic encephalopathy is predominantly clinical, and the tests available assist in the diagnosis only by excluding other causes. Covert hepatic encephalopathy, which is defined as abnormal performance on psychometric tests when standard neurologic examination is completely normal, has gained widespre...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2015.04.001
更新日期：2015-08-01 00:00:00
abstract：:A variety of benign and malignant neoplasms can be encountered in the liver. Hematoxylin and eosin-stained tissue sections alone may not yield sufficient information to definitively diagnose liver tumors; therefore, ancillary studies with immunohistochemical markers can play a crucial role in differentiating the diffe...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2010.10.001
更新日期：2010-11-01 00:00:00
abstract：:Non-alcoholic fatty liver disease (NAFLD) is common and may progress to end-stage liver disease. Liver-related morbidity and mortality occur almost exclusively in patients whose disease progresses to advanced fibrosis and cirrhosis. Presence and severity of liver fibrosis seem the most important indicators of long-ter...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2007.02.004
更新日期：2007-02-01 00:00:00
abstract：:Liver biopsy is used to determine the pathogenesis of liver dysfunction after liver transplantation. One or more causative factors may be identified on biopsy. The pathologist must be familiar with the histopathology of acute rejection to differentiate it from other potential complications, including biliary obstructi...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/s1089-3261(02)00003-x
更新日期：2002-05-01 00:00:00
abstract：:Good management of patients at risk for the development of hepatocellular carcinoma includes regular ultrasound surveillance, and aggressive management of lesions detected at ultrasound. Good radiology and good pathology are essential to the appropriate management of these small lesions. With good quality testing it i...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2007.08.011
更新日期：2007-11-01 00:00:00
abstract：:AMA are detected in the serum of 92% to 95% of patients with PBC using indirect immunofluorescent methods. AIC is the term used to describe the 5% to 8% of AMA-negative PBC patients who uniformly have ANA and SMA. Recent applications of more sensitive and specific tests to detect serum AMA have shown that most, if not...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/S1089-3261(03)00132-6
更新日期：2004-02-01 00:00:00
abstract：:Steatosis is a common finding in patients with chronic hepatitis C (CHC) due to a combination of the direct steatogenic effect of hepatitis C virus (HCV) and the prevalence of metabolic risk factors in the HCV population. Steatosis is now established as a risk factor for disease progression in CHC and significantly im...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2004.06.007
更新日期：2004-11-01 00:00:00
abstract：:Development of ethanol-induced fatty liver, alcoholic hepatitis, and cirrhosis has been attributed in part to nutritional deficiencies for many years. Special attention must be focused on treating alcohol-induced liver disease while providing replacement of deficient amino acids, vitamins, minerals, and other nutrient...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2004.11.003
更新日期：2005-02-01 00:00:00
abstract：:Chronic hepatitis C virus (HCV) infection is the most common indication for liver transplantation in the United States and Europe, and more than 20,000 patients worldwide have undergone transplantation for complications of chronic hepatitis C. In North America, HCV accounts for 15% to 50% of the liver transplants perf...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2005.05.004
更新日期：2005-08-01 00:00:00
abstract：:The management of autoimmune and cholestatic liver disorders is a challenging area of hepatology. Autoimmune and cholestatic liver diseases represent a comparatively small proportion of hepatobiliary disorders, yet their appropriate management is of critical importance for patient survival. In this article, management...
journal_title：Clinics in liver disease
pub_type： 杂志文章
doi：10.1016/j.cld.2009.02.011
更新日期：2009-05-01 00:00:00
abstract：:Nonalcoholic fatty liver disease (NAFLD) is the liver disease associated with obesity, diabetes, and the metabolic syndrome. Although steatosis is a key histologic feature, liver biopsies of patients with NAFLD can show a wide range of findings. Nonalcoholic steatohepatitis (NASH) is a progressive subtype of NAFLD fir...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2015.10.011
更新日期：2016-05-01 00:00:00
abstract：:Acetaminophen (APAP) is the leading worldwide cause of drug overdose and acute liver failure (ALF). Single overdose ingestion and therapeutic misadventure may cause hepatotoxicity. Several factors, such as concomitant alcohol use or abuse, concurrent medications, genetic factors, and nutritional status, can influence ...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2013.07.005
更新日期：2013-11-01 00:00:00
abstract：:Scientists and clinicians have made tremendous advances in understanding the pathogenesis of hepatitis C virus (HCV) infection and have developed impressive strategies for treating this hepatotropic virus in the short time since its discovery in 1989. This article goes beyond the current guidelines for the treatment o...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2006.08.024
更新日期：2006-11-01 00:00:00
abstract：:Liver transplantation in pediatrics has become an accepted modality of treatment in end-stage liver disease and irreversible acute liver failure. Biliary atresia is the most common indication requiring liver transplantation in children. The diagnosis and causes of acute liver failure in children differ from those in a...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2007.04.001
更新日期：2007-05-01 00:00:00
abstract：:There have been major advances in the field of hepatitis B (HBV) over the last few decades. These advances have resulted in the understanding of the natural history of chronic HBV infection, effective vaccines against the virus, sensitive assays for screening and monitoring of treatment, and effective treatments for v...
journal_title：Clinics in liver disease
pub_type： 历史文章,杂志文章,评审
doi：10.1016/j.cld.2010.05.003
更新日期：2010-08-01 00:00:00
abstract：:Pharmacologic management of hepatic encephalopathy includes a broad range of therapies. This article covers the specific mainstays of therapies, such as antimicrobials and laxatives, with an established evidence base. This article also covers newer modalities of therapies, such as fecal microbiota transplant, probioti...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2020.01.005
更新日期：2020-05-01 00:00:00
abstract：:The risk for potential transmission of infectious agents during gastrointestinal (GI) endoscopy is concerning for patients and physicians. However, the instance of infection transmission remains rare after GI endoscopy procedures, with an estimated frequency of 1 in 1.8 million procedures. Endoscopy-related infection ...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2009.11.012
更新日期：2010-02-01 00:00:00
abstract：:The Model for End-stage Liver Disease (MELD) has been demonstrated to be an excellent predictor of survival in patients who have end-stage liver disease. It is derived from the international normalized ratio (INR) of prothrombin time, serum creatinine, and serum total bilirubin. The major use of the MELD score is to p...
journal_title：Clinics in liver disease
pub_type： 杂志文章
doi：10.1016/j.cld.2008.09.001
更新日期：2009-02-01 00:00:00
abstract：:Transjugular intrahepatic portosystemic shunt (TIPS) is a well-established procedure used in the management of complications of portal hypertension. Although the most robust evidence supports the use of TIPS as salvage therapy in variceal hemorrhage, secondary prophylaxis of variceal bleeding, and treatment of refract...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2019.07.004
更新日期：2019-11-01 00:00:00
abstract：:Combination therapy with beta-blockers and endoscopic band ligation (EBL) is the standard prophylaxis of esophageal variceal rebleeding in cirrhosis. Beta-blockers are the backbone of combination therapy, since their benefit extend to other complications of portal hypertension. EBL carries the risk of post-banding ulc...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2014.01.007
更新日期：2014-05-01 00:00:00
abstract：:Drug-induced liver injury (DILI) can be predictable or idiosyncratic and has an estimated incidence of approximately 20 cases per 100,000 persons per year. DILI is a common cause of acute liver failure in the United States. No accurate tests for diagnosing DILI exist, and its diagnosis is based on exclusion of other c...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2016.08.012
更新日期：2017-02-01 00:00:00
abstract：:Increased survival for young liver transplant recipients has greatly improved. Increasing success has led to broader indications, thereby increasing the number of potential recipients. Pediatric liver centers are developing new strategies to cope with the ever-increasing demands for suitable size appropriate grafts. U...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/s1089-3261(05)70125-2
更新日期：2000-08-01 00:00:00
abstract：:Early diagnosis of HCC is possible because certain risk factors for this tumor are known and because sensitive and relatively inexpensive diagnostic tools are available. Early diagnosis of HCC is also possible because of the long phase of asymptomatic tumor growth and the tumor's tendency to grow as a solitary mass in...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/s1089-3261(05)70156-2
更新日期：2001-02-01 00:00:00
abstract：:Autoimmune liver diseases have much in common with each other, and there are clear associations with genetic haplotypes. Elegant studies have shown autoimmune liver disease induced by viruses and drugs. Although there is evidence for nonimmunological events precipitating immune disease, especially in primary sclerosin...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/s1089-3261(05)70005-2
更新日期：1998-05-01 00:00:00
abstract：:Primary biliary cirrhosis is an insidious disease that progresses through the clinical phases: preclinical, asymptomatic, symptomatic, and liver insufficiency. The outlook of patients diagnosed with PBC has improved significantly over the past 2 decades because more patients are being diagnosed earlier in the disease ...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2008.02.012
更新日期：2008-05-01 00:00:00
abstract：:Obesity has become increasingly prevalent, and the number of obese patients in need of liver transplant is expected to continue to increase. In addition, liver disease due to nonalcoholic fatty liver disease is expected to become the leading cause of liver transplantation in the near future. However, obesity remains a...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2016.12.001
更新日期：2017-05-01 00:00:00
abstract：:Mathematical modeling of hepatitis C viral kinetics has been an important tool in understanding hepatitis C virus (HCV) infection dynamics and in estimating crucial in vivo parameters characterizing the effectiveness of HCV therapy. Because of the introduction of direct-acting antiviral agents, there is a need to exte...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2012.09.003
更新日期：2013-02-01 00:00:00
abstract：:Primary biliary cirrhosis (PBC) is characterized by the presence of high-titer disease specific autoantibodies directed against mitochondrial antigens (AMA) of the inner mitochondrial membrane, that are members of the 2-oxo acid complex. Among numerous other autoantibodies found in PBC the focus of ongoing studies is ...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/s1089-3261(03)00104-1
更新日期：2003-11-01 00:00:00
abstract：:Although recent evidence indicates that the quasispecies nature of HCV constitutes a critical strategy for the virus to survive in the host, the mechanisms of viral persistence remain unknown. Similarly, the correlates of immune protection in a limited proportion of individuals who succeed in clearing HCV are still la...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/s1089-3261(05)70200-2
更新日期：2001-11-01 00:00:00
